|
||||||||||||||||||
|
|
||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||
Questions? Please consult our answers to frequently asked questions at http://www.ebioscience.com/faq. DescriptionGoat IgG TrueBlotTM is a unique horseradish peroxidase conjugated anti-goat IgG immunoblotting (second step) reagent. Goat IgG TrueBlotTM enables detection of immunoblotted target protein bands, without hindrance by interfering immunoprecipitating immunoglobulin heavy and light chains. It is easy to generate publication-quality IP/WB data with Goat IgG TrueBlotTM, simply substitute the conventional HRP anti-goat IgG blotting reagent with Goat IgG TrueBlotTM and follow the prescribed protocol for sample preparation and immunoblotting. Note that there are three key procedural considerations: 1. Immunoprecipitate should be completely reduced. 2. Milk should be used as the blocking protein for the immunoblot. BSA is not an effective blocker. 3. Protein A or G beads may be used with the mouse, goat and sheep TrueBlot secondaries but not with the rabbit TrueBlot secondary. Use of protein A or G beads with the rabbit TrueBlot will result in contaminating bands. Components:
Applications ReportedFor research use only, not for diagnostic or therapeutic use. Applications TestedGoat IgG TrueBlot™ is ideal for use in protocols involving immunoblotting of immunoprecipitated proteins. TrueBlot™ preferentially detects the non-reduced form of goat IgG over the reduced, SDS-denatured form of IgG. When the immunoprecipitate is fully reduced immediately prior to SDS-gel electrophoresis, reactivity of Goat IgG TrueBlot™ with the 55 kDa heavy chains and the 23 kDa light chains of the immunoprecipitating antibody is minimized thereby eliminating interference by the heavy and light chains of the immunoprecipitating antibody in IP/immunoblotting applications. Applications include studies examining post-translational modification (e.g., phosphorylation or acetylation) or protein-protein interactions. Goat IgG TrueBlot™ may also be used for detection in immunoblotting assays that do not employ immunoprecipitation. References
Kong, D., L. Xu, Y. Yu, W. Zhu, D.W. Andrews, Y. Yoon, and T.H. Kuo. 2005. Regulation of Ca2+-induced permeability transition by BCL-2 is antagonized by Drp1 and hFis1. Molecular and Cellular Biochemistry. 272: 187-199. (Rabbit IgG TrueBlot, PubMed) DiPerna, G., J. Stack, A.G. Bowie, A. Boyd, G. Kotwal, Z. Zhang, S. Arvikar, E. Latz, K.A. Fitzgerald, and W.L. Marshall. 2004. Poxvirus protein N1L targets the I-κB Kinase complex, inhibits signaling to NF-κB by the Tumor Necrosis Factor superfamily of receptors, and inhibits NF-κB and IRF3 signaling by Toll-like Receptors. J. Biol. Chem. 279: 36570-36578. (Rabbit IgG TrueBlot, PubMed) Zhang, X., Y. Ozawa, H. Lee, Y. Wen, T. Tan, B. Wadzinski, and E. Seto. 2005. Histone deacetylase 3 (HDAC3) activity is regulated by interaction with protein serine/threonine phosphatase 4. Genes & Development. 19: 827-839. (Rabbit IgG TrueBlot, PubMed) Lehtonen, S., E. Lehtonen, K. Kudlicka, H. Holthöfer, and M.G. Farquhar. 2004. Nephrin Forms a Complex with Adherens Junction Proteins and CASK in Podocytes and in Madin-Darby Canine Kidney Cells Expressing Nephrin. Am J Pathol. 165:923-936. (Rabbit IgG TrueBlot, PubMed) Tyagi A, Agarwal C, Harrison G, Glode LM, Agarwal R. 2004. Silibinin causes cell cycle arrest and apoptosis in human bladder transitional cell carcinoma cells by regulating CDKI-CDK-cyclin cascade, and caspase 3 and PARP cleavages. Carcinogenesis. 25: 1711-20. (Mouse IgG TrueBlot, PubMed) Okoshi Y, Tahara-Hanaoka S, Nakahashi C, Honda S, Miyamoto A, Kojima H, Nagasawa T, Shibuya K, Shibuya A. 2005. Requirement of the tyrosines at residues 258 and 270 of MAIR-I in inhibitory effect on degranulation from basophilic leukemia RBL-2H3. Int Immunol. 17(1):65-72. (Mouse IgG TrueBlot, PubMed) Murray, J., M.F. Marusich, R.A. Capaldi, and R. Aggeler. 2004. Focused proteomics: Monoclonal antibody-based isolation of the oxidative phosphorylation machinery and detection of phosphoproteins using a fluorescent phosphoprotein gel stain. Electrophoresis. 25:2520-2525. (Mouse IgG TrueBlot, PubMed) Hamdane, M., A. Bretteville, A. Sambo, K. Schindowski, S. Begard, A. Delacourte, P. Bertrand, and L. Buee. 2005. p25/Cdk5-mediated retinoblastoma phosphorylation is an early event in neuronal cell death. Journal of Cell Science. 118: 1291-1298. (Rabbit and Mouse IgG TrueBlot, PubMed) Related ProductsCat. 88-1688 Rabbit TrueBlot™ Set (includes 2.5 ml IP Beads, binds 2.5mg Ig/ml beads) Cat. 00-8800 TrueBlot™ anti-Rabbit Ig IP Beads (Binds 2.5mg Ig/ml beads) Cat. 00-8811 TrueBlot™ anti-Mouse Ig IP Beads (Binds 0.4mg Ig/ml beads) Cat. 18-8814 Goat TrueBlot™: Horseradish Peroxidase (HRP) anti-goat IgG Cat. 00-8844 TrueBlot™ anti-Goat Ig IP Beads (Binds 1.0mg Ig/ml beads) Cat. 18-8877 See Catalog # 18-8817 for an alternative product: Mouse TrueBlot™: Horseradish Peroxidase (HRP) anti-mouse IgG Cat. 88-8884 Goat TrueBlot™ Western Blot Kit Experimental ProceduresProcedure: Preparation of Immunoprecipitated Sample for SDS-PAGE
Procedure: Immunoblotting (Western Blotting, WB)
Other Procedural Notes1. Titration of primary IP antibody. Titration of the immunoprecipitating antibody is recommended (e.g., 1-5 µg / 107 cells / 1 ml lysate). Typically, 2 µg is a sufficient amount of antibody to maximally immunoprecipitate most antigens in 1 ml of extract from 1 x 107 cells. Using as little IP antibody as possible minimizes potential contamination of SDS reduced sample with nonreduced immunoprecipitating antibody light chain. 5 µg of immunoprecipitating antibody per ml of extract from 0.5 x 107 - 1.0 x 107 cells yields sample loads of 0.5-1.5 µg immunoprecipitating antibody and precipitates from1 x 106- 3 x 106 cells. Goat IgG TrueBlot™ will not improve the specificity of immunoblotting antibody. If the immunoblotting antibody cross-reacts with proteins other than the target, the bound immunoblotting antibody will be detected by TrueBlot™. 2. Blocking the immunoblot. Goat IgG TrueBlot™ has been extensively tested in blotting conditions that employ 5% (w/v) nonfat milk powder for blocking, 5% (w/v) nonfat milk powder for immunoblotting with primary antibody, and 5% (w/v) nonfat milk powder for incubation with TrueBlot™. Blocking solution is made from 25 mM Tris, pH 7.3, 0.15 M NaCl, and 0.1% Tween-20. Always readjust pH to 7.3 after addition of nonfat milk powder, which acidifies the buffer. Use of other proteins for blocking and incubation with immunoblotting antibody and TrueBlot™ is not recommended. The use of BSA for blocking is specifically not recommended. 3. Positive control. Goat IgG TrueBlot™ will detect SDS-denatured, non-reduced goat IgG. A 20 ng sample of non-reduced, immunoprecipitating antibody can be included in the immunoblot as a positive control to ensure positive performance of TrueBlot™. 4. Negative control. Sample containing 0.5-2.0 µg of reduced goat IgG (prepared and run immediately as described in Sample Preparation) can be included as a negative control to ensure that TrueBlot™ does not detect the heavy and light chain of the immunoprecipitating antibody. Other potential controls include omitting the cell extract during the IP, omitting the IP antibody during the IP, or omitting the immunoblotting antibody. 5. SDS-PAGE. Goat IgG TrueBlot™ has been tested in procedures that employed anti-oxidant in the running buffer, staining of the membrane with Ponceau S Solution (Sigma) followed by destaining with 20% acetic acid/30% methanol, and air drying the membrane for 1 hour at room temperature after transfer and then rewetting in methanol and equilibration in Buffer A (described in Immunoblotting Protocol) before blocking. These modifications of the protocol gave results identical to the Immunoblotting Protocol. The Immunoblotting Protocol has not included these variations. Additional information: For updated information on this product. Experimental Example
Troubleshooting
TrueBlot™ is a Trademark of eBioscience - Patent Pending |
|||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() |
![]() |
|
Copyright © 2000-2008 eBioscience, Inc. Product For Research Use Only: Not for further distribution without written consent. |